HPMC & sodium hyaluronate cause IOP increases

Article

Sodium hyaluronate 1% and hydroxypropylmethylcellulose 2% (HPMC) can cause significant intraocular pressure (IOP) increases during the first eight hours following cataract surgery.

Sodium hyaluronate 1% and hydroxypropylmethylcellulose 2% (HPMC) can cause significant intraocular pressure (IOP) increases during the first eight hours following cataract surgery, according to a study published in the June issue of Ophthalmology.

Georg Rainer and colleagues from the Medical University of Vienna, Austria enrolled 80 eyes of 40 patients with bilateral age-related cataract. The subjects were randomized to receive either sodium hyaluronate 1% or HPMC 2% during cataract surgery of the first eye. The second eye received an alternative viscosurgical device. IOP was measured preoperatively and 30 minutes, one, two, three, four, six, eight, 20 and 24 hours and one week postoperatively.

The researchers found that the highest mean IOP increase occurred at eight hours postoperatively (5.3±6.4 mmHg) in the sodium hyaluronate 1% group and at two hours postoperatively in the HPMC 2% group (7.8±6.1 mmHg). The mean IOP increase was higher in the HPMC 2%group (r=0.005). IOP spikes (≥30 mmHg) were seen in five eyes (13%) of the sodium hyaluronate 1% group and 13 eyes (33%) of the HPMC 2% group.

It was concluded from the study results that both sodium hyaluronate 1%% and HPMC 2% can cause significant IOP increases during the first eight hours following surgery.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.